medicine-technology-1/oxygen-biotherapeutics--inc--announces-1-3a15-reverse-stock-split-to-take-effect-nov--9--2009-6067-1/;/a><br

Breaking Biology Technology:Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2 Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6 Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2 Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2 Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3 Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4

[0] Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. [0] RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)[0] Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)[0] Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe

Breaking Medicine Technology:The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2 The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3 The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4 The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5 Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2 Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3 TOMORROW 3A Lets Get It Done 3A Organizing for America to Host Spanish Language Forum on Health Insurance Reform Now in Tucson with Rep Raul Grijalva 56274 1 TOMORROW 3A Lets Get It Done 3A Organizing for America to Host Spanish Language Forum on Health Insurance Reform Now in Tucson with Rep Raul Grijalva 56274 2 Boston Scientific to Participate in Thomas Weisel Partners Health Care Conference 56269 1 Boston Scientific to Participate in Thomas Weisel Partners Health Care Conference 56269 2 Labor Day Event to Offer Angelenos Unique Opportunity to Learn About Healthcare Reform and Send a Strong Message to Washington D C 21 56265 1 Labor Day Event to Offer Angelenos Unique Opportunity to Learn About Healthcare Reform and Send a Strong Message to Washington D C 21 56265 2

[0] The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies [0] Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting [0] Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program